hydrocortisone plus fludrocortisone

ApprovedSmall molecule

hydrocortisone plus fludrocortisone is one of 25 small molecule programs targeting Septic Shock. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Septic ShockApproved

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

hydrocortisone plus fludrocortisone

NNorthern Jiangsu People's Hospital

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Avastin

BBio-Thera Solutions

Preclinical

1 8

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Cardiac Surgery

NCT07037043

Q4 2028

Post-ApprovalRecruiting

Septic Shock

NCT07383103

Clinical

Trials by Indication[1]

Cardiac Surgery1 trial

Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery

Not yet recruiting·—·Phase 3·NCT07037043·196 enrolled

Septic Shock1 trial

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

Recruiting·NNorthern Jiangsu People's Hospital·Phase 4·NCT07383103·336 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for hydrocortisone plus fludrocortisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hydrocortisone plus fludrocortisone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hydrocortisone plus fludrocortisone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northern Jiangsu People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNorthern Jiangsu People's Hospital

hydrocortisone plus fludrocortisone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Cardiac Surgery1 trial

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News